Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833211 | 0.90 | USP2 (0.46) | SMN1; SMN2USP2RECQLGLACHRM2 | |
| SCHEMBL11995195 | 0.85 | USP2 (0.56) | SMN1; SMN2USP2RECQLCHRM2CHRM1 | |
| Tetrahydrofuran SCHEMBL28264888 | 0.78 | USP2 (0.50) | SMN1; SMN2USP2RECQLCHRM2CHRM1 | |
| SCHEMBL1563999 | 0.77 | USP2 (0.49) | SMN1; SMN2USP2RECQLCTSKUSP30 | |
| SCHEMBL13683346 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2RECQLGPR119CTSK | |
| SCHEMBL513188 | 0.77 | USP2 (0.43) | SMN1; SMN2USP2CHRM2CHRM1CHRM3 | |
| SCHEMBL1280597 | 0.74 | USP2 (0.63) | SMN1; SMN2USP2RECQLGPR119RAB9A | |
| SCHEMBL3449401 | 0.74 | RECQL (0.54) | SMN1; SMN2USP2RECQLGPR119KDM4E | |
| SCHEMBL31218507 | 0.74 | CHRM2 (0.44) | SMN1; SMN2USP2CHRM2CHRM1CHRM3 | |
| SCHEMBL205421 | 0.74 | LMNA (0.48) | SMN1; SMN2USP2RECQLCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060034-A | Preparation method of pyran-substituted morpholine compound | 上海信诺维生物医药有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-116751173-A | Green synthesis method of drug intermediate | 易简和成(江苏)医药科技有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-115947697-A | Synthesis method of 3-oxomorpholine-4-carboxylic acid tert-butyl ester | 苏州汉德创宏生化科技有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-102617503-B | Novel synthetic method of (S)-3-morpholinyl carboxylic acid | CHAINPHARM BIO MEDICAL CO LTD | 2014-05-07 | — | — | CN | claimed |
| CN-102617503-A | Novel synthetic method of (S)-3-morpholinyl carboxylic acid | CHAINPHARM CO LTD | 2012-08-01 | — | — | CN | claimed |
| US-12636372-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-12622981-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12527882-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250381276-A1 | SMALL MOLECULE CONJUGATED CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4615508-A1 | CHARGE-ALTERING NUCLEIC ACID TRANSPORTERS WITH BETA-AMIDO CARBONATE BACKBONES | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2013049719-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049719-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| CN-102803226-A | Cycloalkyl-substituted imidazole derivatives | DAIICHI SANKYO CO LTD | 2012-11-28 | — | — | CN | disclosed |
| CN-102617503-A | Novel synthetic method of (S)-3-morpholinyl carboxylic acid | CHAINPHARM CO LTD | 2012-08-01 | — | — | CN | disclosed |
| WO-2012021712-A1 | TETRACYCLINE ANALOGS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| CN-101801955-A | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | ARRAY BIOPHARMA INC | 2010-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622981-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | NPC1L1, NPC1, SCP2 | SMN1; SMN2 449/4885USP2 3621/4885RECQL 2338/4885 |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | SMN1; SMN2 3689/4885USP2 3107/4885RECQL 3073/4885 |
| US-12636372-B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | NPC1L1, NPC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 540/4885USP2 2110/4885RECQL 1472/4885 |
| US-20250381276-A1 | SMALL MOLECULE CONJUGATED CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | SLC43A1, SLC7A5, SLC7A1 | SMN1; SMN2 2275/4885USP2 4116/4885RECQL 1148/4885 |
| US-12527882-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | CCRL2, HAVCR2, CCR3 | SMN1; SMN2 536/4885USP2 2124/4885RECQL 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.